Clinical Trial

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Name: A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease — clinical trial record (NCT07214727)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

Protocol Amendment History 1 change

notable Trial sites expanded: 6 -> 11 locations 2026-04-21

Trial Details

NCT Number	NCT07214727
Lead Sponsor	Alnylam Pharmaceuticals Collaborators: Regeneron Pharmaceuticals
Conditions	Alzheimer's Disease
Enrollment	50 participants
Start Date	2025-10-15
Primary Completion	2030-03-06 (estimated)
Study Completion	2030-03-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-14